Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Ciliatech receives FDA investigational device exemption for glaucoma uveal spacer
5+ day, 10+ hour ago (53+ words) The FDA has granted investigational device exemption to Ciliatech’s Intercil uveal spacer for glaucoma, according to a company press release. With the approval, the company plans to begin a new feasibility study to evaluate the safety and performance of the…...
RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results
1+ week, 10+ hour ago (74+ words) TradingView RNTX: LTI-03 advances in Phase 2 IPF trials after promising safety and biomarker results LTI-03, a novel inhaled peptide, showed strong antifibrotic and regenerative effects in preclinical and early clinical studies, with a favorable safety profile and biomarker activity. The…...
Leber Hereditary Optic Neuropathy Treatment Market Demonstrates Long-Term Growth Potential At 7.6% CAGR
3+ week, 2+ day ago (62+ words) openPR.com Leber Hereditary Optic Neuropathy Treatment Market Demonstrates Long-Term Growth Potential At 7.6% CAGR Press release from: The Business Research Company Permanent link to this press release: You can edit or delete your press release Leber Hereditary Optic Neuropathy Treatment…...